Skip to content
value.today

858 Therapeutics, Inc.

🇺🇸 San Diego, California, USAPharmaceuticalsFounded 2019
Total raised
$65 M
3 rounds on record
Latest round
$25 M
Jun 2024
First round on record
Mar 2020
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of 858 Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2024$25 MNo. 3$10 to $50 million

858 Therapeutics, Inc.: Raise no. 3, Jun 2024

Investors in this round

12 investors had bought by the notice of Jul 11, 2024: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $50 M offered; $25 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Veal · Executive Officer
  • Katherine Bell-McGuinn · Executive Officer
  • Stafford Jeffrey · Executive Officer, Director
  • Ali Behbahani · Director
  • Clare Ozawa · Director
  • Jane Huang · Director
  • Monal Mehta · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey A. Stafford, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 11, 2024. Read the notice at the SEC.

equitySEC
May 2021$20 MNo. 2$10 to $50 million

858 Therapeutics, Inc.: Raise no. 2, May 2021

Investors in this round

6 investors had bought by the notice of May 18, 2021: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $40 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Veal · Executive Officer
  • Jeffrey A. Stafford · Executive Officer, Director
  • Ali A. Behbahani · Director
  • Carlo Rizzuto · Director
  • Clare Ozawa · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey A. Stafford, President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 18, 2021. Read the notice at the SEC.

equitySEC
Mar 2020$20 MNo. 1$10 to $50 million

858 Therapeutics, Inc.: Raise no. 1, Mar 2020

Investors in this round

1 investor had bought by the notice of Mar 11, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $38 M offered; $17 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James J. Veal · Executive Officer
  • Bradley J. Bolzon · Director
  • Clare J. Ozawa · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total amount sold includes the shares sold upon conversion of an outstanding convertible note.”

Signed by Jeffrey A. Stafford, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 11, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • 858 Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2024).

    SEC Form D · Jul 2024

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jul 2024

That is all the official record says: 858 Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of 858 Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 12 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by 858 Therapeutics, Inc.
NameRoleNamed in
James VealExecutive officerJul 2024
Katherine Bell-McGuinnExecutive officerJul 2024
Stafford JeffreyExecutive officerJul 2024
Jeffrey A. StaffordExecutive officerMay 2021
James J. VealExecutive officerMar 2020
Ali BehbahaniDirectorJul 2024
Clare OzawaDirectorJul 2024
Jane HuangDirectorJul 2024
Monal MehtaDirectorJul 2024
Stafford JeffreyDirectorJul 2024
Ali A. BehbahaniDirectorMay 2021
Carlo RizzutoDirectorMay 2021
Jeffrey A. StaffordDirectorMay 2021
Bradley J. BolzonDirectorMar 2020
Clare J. OzawaDirectorMar 2020